SQZ Biotechnologies Company (SQZB)
- Previous Close
0.0465 - Open
0.0465 - Bid --
- Ask --
- Day's Range
0.0465 - 0.0465 - 52 Week Range
0.0100 - 0.6720 - Volume
16 - Avg. Volume
179,503 - Market Cap (intraday)
1.371M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4300 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.00
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
www.sqzbiotech.comRecent News: SQZB
Performance Overview: SQZB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SQZB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SQZB
Valuation Measures
Market Cap
1.37M
Enterprise Value
12.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.11
Price/Book (mrq)
0.73
Enterprise Value/Revenue
1.04
Enterprise Value/EBITDA
-0.26
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.14%
Return on Equity (ttm)
-203.37%
Revenue (ttm)
12.12M
Net Income Avi to Common (ttm)
-71.64M
Diluted EPS (ttm)
-2.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
10.19M
Total Debt/Equity (mrq)
1,141.52%
Levered Free Cash Flow (ttm)
-29.51M